Total Equity
Veralto Total Equity decreased by 3.2% to $3.01B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 30.5%, from $2.30B to $3.01B. Over 3 years (FY 2022 to FY 2025), Total Equity shows relatively stable performance with a -1.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase generally signals growth in retained earnings or capital injections, while a decrease may indicate share buybacks, dividend payments, or net losses.
Detailed definition
This represents the residual interest in the assets of the entity after deducting all its liabilities. It reflects the n...
Peer comparison
Standard across all public companies; peers in the medical device and diagnostics sector typically maintain high equity levels to support R&D and M&A.
total_stockholders_equityHistorical Data
| Q4 '22 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.24B | $1.04B | $1.38B | $1.48B | $1.67B | $1.95B | $2.04B | $2.30B | $2.65B | $2.85B | $3.11B | $3.01B |
| QoQ Change | — | -67.9% | +33.2% | +7.2% | +12.4% | +17.3% | +4.3% | +13.0% | +15.2% | +7.3% | +9.1% | -3.2% |
| YoY Change | — | — | -57.2% | — | — | +88.2% | +47.4% | +55.3% | +59.2% | +45.7% | +52.4% | +30.5% |
Total Equity at Other Companies
Frequently Asked Questions
- What is Veralto's total equity?
- Veralto (VLTO) reported total equity of $3.01B in Q1 2026.
- How has Veralto's total equity changed year-over-year?
- Veralto's total equity increased by 30.5% year-over-year, from $2.30B to $3.01B.
- What is the long-term trend for Veralto's total equity?
- Over 3 years (2022 to 2025), Veralto's total equity has grown at a -1.4% compound annual growth rate (CAGR), from $3.24B to $3.11B.
- What does total equity mean?
- The total value of the company that belongs to the shareholders after all debts are paid.